[go: up one dir, main page]

SI1945665T1 - Terapevtska sredstva na osnovi protiteles s povečano ADCC aktivnostjo - Google Patents

Terapevtska sredstva na osnovi protiteles s povečano ADCC aktivnostjo

Info

Publication number
SI1945665T1
SI1945665T1 SI200631261T SI200631261T SI1945665T1 SI 1945665 T1 SI1945665 T1 SI 1945665T1 SI 200631261 T SI200631261 T SI 200631261T SI 200631261 T SI200631261 T SI 200631261T SI 1945665 T1 SI1945665 T1 SI 1945665T1
Authority
SI
Slovenia
Prior art keywords
antibody
adcc activity
based therapeutics
enhanced adcc
enhanced
Prior art date
Application number
SI200631261T
Other languages
English (en)
Slovenian (sl)
Inventor
John M Mcpherson
Tim Edmunds
Qun Zhou
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of SI1945665T1 publication Critical patent/SI1945665T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
SI200631261T 2005-10-21 2006-10-20 Terapevtska sredstva na osnovi protiteles s povečano ADCC aktivnostjo SI1945665T1 (sl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72894705P 2005-10-21 2005-10-21

Publications (1)

Publication Number Publication Date
SI1945665T1 true SI1945665T1 (sl) 2012-03-30

Family

ID=37963422

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200631261T SI1945665T1 (sl) 2005-10-21 2006-10-20 Terapevtska sredstva na osnovi protiteles s povečano ADCC aktivnostjo

Country Status (13)

Country Link
US (2) US7700321B2 (fr)
EP (1) EP1945665B1 (fr)
JP (1) JP5583908B2 (fr)
AR (1) AR058129A1 (fr)
AT (1) ATE536373T1 (fr)
CA (1) CA2626556C (fr)
CY (1) CY1112446T1 (fr)
DK (1) DK1945665T3 (fr)
ES (1) ES2376083T3 (fr)
PL (1) PL1945665T3 (fr)
PT (1) PT1945665E (fr)
SI (1) SI1945665T1 (fr)
WO (1) WO2007048122A2 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7749094B2 (en) * 2003-12-29 2010-07-06 Chen Yung Hsiang Golf club grip and manufacturing method thereof
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
EP2388273B1 (fr) * 2005-10-21 2017-07-05 LFB USA, Inc. Anticorps avec activité cytotoxique cellulaire améliorée dépendant des anticorps, leurs procédés de production et utilisation
ATE536373T1 (de) * 2005-10-21 2011-12-15 Genzyme Corp Therapiemittel auf antikörperbasis mit erhöhter adcc-aktivität
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
CA2663536A1 (fr) * 2006-10-24 2008-05-02 Trubion Pharmaceuticals, Inc. Module de dispositif electronique comprenant un copolymere de polyolefine
US7846434B2 (en) 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
CA2685222C (fr) 2007-05-14 2017-12-19 Medimmune, Llc Methodes de reduction des taux d'eosinophiles
MX2010008570A (es) 2008-02-05 2010-08-30 Bristol Myers Squibb Co Anticuerpos alfa5-beta1 y sus usos.
AU2009223054A1 (en) * 2008-03-11 2009-09-17 Genentech, Inc. Antibodies with enhanced ADCC function
EP2279003A4 (fr) * 2008-05-01 2013-04-03 Gtc Biotherapeutics Inc Anticorps anti-cd137 en tant qu'agent dans le traitement d'états inflammatoires
CA2723197C (fr) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Procede et compositions pour preparer des anticorps et des derives d'anticorps avec une fucosylation centrale reduite
AP2011005984A0 (en) 2009-04-20 2011-12-31 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17.
US20110039300A1 (en) * 2009-08-10 2011-02-17 Robert Bayer Antibodies with enhanced adcc functions
WO2011047083A1 (fr) 2009-10-13 2011-04-21 Oxford Biotherapeutics Ltd. Anticorps anti-epha10
EP2539370B1 (fr) * 2010-02-23 2019-05-15 Sanofi Anticorps anti-intégrine alpha-2 et leurs utilisations
PL2608796T3 (pl) 2010-08-05 2019-04-30 Seattle Genetics Inc Hamowanie fukozylacji białka w warunkach in vivo za pomocą analogów fukozy
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
ES2724801T3 (es) 2011-04-19 2019-09-16 Pfizer Combinaciones de anticuerpos anti-4-1BB y anticuerpos inductores de ADCC para el tratamiento del cáncer
FR2976811A1 (fr) 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
CN103649121B (zh) 2011-06-28 2016-10-19 牛津生物疗法有限公司 针对adp-核糖基环化酶2的抗体
US20130149300A1 (en) * 2011-09-27 2013-06-13 Icon Genetics Gmbh MONOCLONAL ANTIBODIES WITH ALTERED AFFINITIES FOR HUMAN FCyRI, FCyRIIIa, AND C1q PROTEINS
ES3027182T3 (en) 2011-12-23 2025-06-13 Pfizer Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2014004549A2 (fr) 2012-06-27 2014-01-03 Amgen Inc. Protéines de liaison anti-mésothéline
RU2681730C2 (ru) 2012-07-25 2019-03-12 Селлдекс Терапьютикс Инк. Антитела против kit и их применения
EP2887947B1 (fr) 2012-08-23 2019-06-05 Seattle Genetics, Inc. Analogues de la fucose destinées au traitement de la drépanocytose
EP3514175A1 (fr) 2012-12-17 2019-07-24 Laboratoire Français du Fractionnement et des Biotechnologies Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
KR20160002713A (ko) 2013-02-13 2016-01-08 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도
CN105263319A (zh) 2013-02-13 2016-01-20 法国化学与生物科技实验室 具有经修饰的糖基化的蛋白及其生产方法
ES2847383T3 (es) 2013-03-15 2021-08-03 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
US10501737B2 (en) 2013-09-30 2019-12-10 Chugai Seiyaku Kabushiki Kaisha Method for producing antigen-binding molecule using modified helper phage
FR3016633B1 (fr) 2014-01-17 2018-04-13 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Immunoglobuline anti-toxine du charbon
KR101660580B1 (ko) 2014-04-02 2016-09-28 프레스티지 바이오파마 피티이. 엘티디. 항체의 당 함량 조절을 통한 항체의 제조 방법
TW201629215A (zh) * 2014-09-30 2016-08-16 拜耳保健有限責任公司 使用凝血酶之組成物及治療方法
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP3356415B1 (fr) 2015-09-29 2024-05-01 Amgen Inc. Inhibiteurs de l'asgr pour réduire les taux de cholestérol
ES2990113T3 (es) 2016-07-07 2024-11-28 The Board Of Trustees Of The Leland Stanfordjunior Univ Conjugados de adyuvantes de anticuerpos
JP2020514273A (ja) * 2016-12-22 2020-05-21 サノフイＳａｎｏｆｉ 白斑症の処置のための抗ヒトｃｘｃｒ３抗体
KR20190095943A (ko) * 2016-12-22 2019-08-16 사노피 고갈 활성을 갖는 인간화 cxcr3 항체 및 이의 사용 방법
WO2018119288A1 (fr) * 2016-12-22 2018-06-28 Sanofi Anticorps anti-cxcr3 humains pour le traitement du vitiligo
ES2994451T3 (en) 2017-04-20 2025-01-24 Atyr Pharma Inc Compositions for treating lung inflammation
EP3625256A1 (fr) 2017-05-19 2020-03-25 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anticorps monoclonal humain ciblant tnfr2 en immunothérapie anticancéreuse
WO2020190725A1 (fr) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugués ciblant le her2
EP4073067A1 (fr) * 2019-12-12 2022-10-19 Fresenius Kabi Deutschland GmbH Polypeptides glycosylés
EP4076490A1 (fr) 2019-12-20 2022-10-26 Bristol-Myers Squibb Company Utilisation d'un inhibiteur de fucosylation pour produire un anticorps afucosylé
MX2024002611A (es) 2021-08-30 2024-05-29 Lassen Therapeutics 1 Inc Anticuerpos anti-il-11ra.
IL321948A (en) 2023-01-06 2025-09-01 Lassen Therapeutics Inc Anti-IL-18 BP antibodies
CN120787238A (zh) 2023-01-06 2025-10-14 拉森医疗公司 用于治疗甲状腺眼病的抗IL-11Rα抗体
CN120858108A (zh) 2023-01-06 2025-10-28 拉森医疗公司 抗il-18bp抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DK1071700T3 (da) * 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2278003B2 (fr) 1999-04-09 2020-08-05 Kyowa Kirin Co., Ltd. Procédé de contrôle de l'activité de molécule fonctionnelle immunologique
US6642038B1 (en) * 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US20030124653A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Method of producing glycoproteins having reduced complex carbohydrates in mammalian cells
ATE536373T1 (de) 2005-10-21 2011-12-15 Genzyme Corp Therapiemittel auf antikörperbasis mit erhöhter adcc-aktivität

Also Published As

Publication number Publication date
ES2376083T3 (es) 2012-03-08
US20070092521A1 (en) 2007-04-26
WO2007048122A2 (fr) 2007-04-26
US7700321B2 (en) 2010-04-20
PL1945665T3 (pl) 2012-02-29
US8071336B2 (en) 2011-12-06
ATE536373T1 (de) 2011-12-15
DK1945665T3 (da) 2012-02-06
EP1945665A2 (fr) 2008-07-23
JP5583908B2 (ja) 2014-09-03
AR058129A1 (es) 2008-01-23
CA2626556A1 (fr) 2007-04-26
EP1945665B1 (fr) 2011-12-07
CA2626556C (fr) 2016-05-10
PT1945665E (pt) 2012-04-20
JP2009512697A (ja) 2009-03-26
US20100184145A1 (en) 2010-07-22
CY1112446T1 (el) 2015-12-09
WO2007048122A3 (fr) 2007-09-20

Similar Documents

Publication Publication Date Title
SI1945665T1 (sl) Terapevtska sredstva na osnovi protiteles s povečano ADCC aktivnostjo
GB2444443B (en) Knitting techniques
GB0702701D0 (en) Extra width dishwasher
PT1874927E (pt) Celulases melhoradas
EP1956989A4 (fr) Filetage a angle inverse avec espace libre anti-evasement
EP2003357A4 (fr) Siège
ZA200709451B (en) Catalyst manufacture
EP1854538A4 (fr) Composition catalytique
GB2458416B (en) Seat track assembly
EP1877961A4 (fr) Stylo de signalisation
PL1733674T3 (pl) Zmywarka do naczyń
ZA200707570B (en) Catalyst composition
GB0623879D0 (en) Interpolating decoder
EP1992256A4 (fr) Siège
GB0612662D0 (en) Seat
EP1874979A4 (fr) Réacteur
PL1762170T3 (pl) Zmywarka
GB0503877D0 (en) Time piece
TWM291329U (en) Paint-dotting pen structure
GB0509642D0 (en) Therapeutics agents
GB0522073D0 (en) Bio power-7
AU307490S (en) Pen
AU307569S (en) Pen
GB0611518D0 (en) Convertible seat
PH32006000524S1 (en) Writing utensils